Halozyme Therapeutics HALO Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's other comprehensive income unrealized holding gain loss on securities arising during period net of tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's other comprehensive income unrealized holding gain loss on securities arising during period net of tax?
- Halozyme Therapeutics (HALO) reported other comprehensive income unrealized holding gain loss on securities arising during period net of tax of -$3K in Q1 2026.
- How has Halozyme Therapeutics's other comprehensive income unrealized holding gain loss on securities arising during period net of tax changed year-over-year?
- Halozyme Therapeutics's other comprehensive income unrealized holding gain loss on securities arising during period net of tax decreased by 101.6% year-over-year, from $189K to -$3K.